MedTrace Logo

The ATP Project (Antipsychotic-TEP-Psychosis)

NCT06651112 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2024-11-08

No results posted yet for this study

Summary

The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.

The main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose).

Participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).

Conditions

  • First Episose Psychosis
  • Metabolic Disease
  • Psychosis; Episode

Interventions

DRUG

Antipsychotic drugs

Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton

Sponsors & Collaborators

  • Baszucki Brain Research Fund

    collaborator OTHER

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Stephen Cunnane, Ph.D · Université de Sherbrooke

  • Kevin Zemmour, MD · Université de Sherbrooke

  • Maggie Hahn, MD · University of Toronto

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2026-11-01
Completion
2027-06-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06651112 on ClinicalTrials.gov